Age-related macular degeneration (AMD) is the main cause of permanent and irreversible vision loss in the elderly. It is a degenerative disease of the macula that causes central vision loss in patients, which influences patients' visual functions, such as reading, driving, face, and color recognition. However, many people with early or intermediate AMD show no symptoms, so they don’t realize they have the disease until their vision becomes very blurry. Macular degeneration is a multifactorial disease and its related mechanism is still being explored, but it is believed that long-term light damage, genetics, metabolism, chronic inflammation, immune response, and other factors can all lead to the occurrence of AMD.
AMD is clinically divided into two main categories, dry (non-exudative or atrophic) AMD and wet (exudative or neovascular) AMD. Dry AMD is characterized by subchoroidal drusen deposition and geographic atrophy, while wet AMD is characterized by choroidal neovascularization and damage to the macula.
Dry AMD causes changes in the retinal pigment epithelium, typically seen as dark pin-spotted areas. The pathogenesis is the slow progressive atrophy of photoreceptors, retinal pigment epithelium (RPE), and choriocapillary layer. A simple analogy is that something similar to age spots grows in the macular area, called drusen. These drusen can result in the loss of central vision, although they do not cause total blindness. The onset of dry AMD tends to be relatively slow, with no symptoms in the early stage, followed by gradual loss of binocular vision, and visual distortion.
Wet AMD develops new abnormal blood vessels under the retina in a process called choroidal neovascularization (formation of abnormal blood vessels). Wet AMD progresses rapidly, and if it is not treated in time, vision will decline rapidly in a short period of time, and even lead to blindness.
The construction of AMD animal models is of great significance to deeply understand its pathogenesis. Cyagen can provide animal models of AMD constructed by gene editing, laser modeling, drug induction, and more.
1. Model of retinal neovascularization: Humanized VEGF overexpression transgenic mice
The humanized VEGF (hVEGF) overexpression transgenic (TG) mouse model constructed by Cyagen for neovascular AMD disease can spontaneously develop relevant disease pathology, including obvious lesions appearing while maintaining the intact eyeball structure, which can be used for drug evaluation and related research of neovascular AMD disease.
Figure 1. Schematic diagram of the construction strategy for humanized VEGFA overexpression mice (TG).
Figure 2. FFA of 6-week-old and 7-week-old hVEGF transgenic mice (F0 generation, TG); the results showed that the eyeballs of F0 generation hVEGF mice showed obvious local fluorescein leakage and obvious vascular lesions in FFA detection. The lesions persisted with increasing weeks of age.
Figure 3. The optical coherence tomography (OCT) results of 6-week-old hVEGF mice (F0 generation, TG); compared with C57BL/6J mice of the same age, the eyeballs of F0 generation hVEGF mice showed local structural disorder in the retinal near-choroidal layer in OCT detection.
Figure 4. The electroretinogram (ERG) results of 6-week-old hVEGF mice (F0 generation, TG); compared with C57BL/6J mice of the same age, the ERG results of F0 generation hVEGF mice showed no such difference, which means the current degree of lesions has not affected the photoreceptors.
2. Laser-induced choroidal neovascularization model (Neovascular AMD)
Through classical laser photocoagulation, Cyagen uses a laser to destroy the outer retina and Bruch's membrane, resulting in the formation of choroidal neovascularization (CNV), which mimics the hallmark pathology observed in neovascular AMD (a.k.a. wet macular degeneration). The incidence of CNV can be evaluated by Fundus fluorescein angiography (FFA), OCT scan, and pathological tissue slide observation.
Figure 5. Laser-induced CNV (choroidal neovascularization) results in targeted laser damage by fundus laser photocoagulation of RPE and Bruch's membrane which induces angiogenesis that mimics the hallmark pathology observed in neovascular AMD. FFA performed 3 days after surgery showed that there was significant fluorescein leakage at the stimulated spot with clear outline, but compared with the gene editing (transgenic) model, the lesion persisted for a shorter time, making the operation more difficult and less repeatable.
Figure 6. The efficacy test results of Aflbercept, injected through the vitreous cavity, are shown in the figure above.
Figure 7.The OCT test showed that after Aflibercept injection, the volume of L-CNV lesions on D7 and D14 days was significantly reduced compared to the data of PBS injection control group.
3. Drug-induced dry AMD model: sodium iodate NaIO3-induced dry AMD mouse model
Cyagen uses sodium iodate NaIO3 to induce a dry AMD mouse model. After injecting NaIO3 into the tail vein of mice, the phenotype of dry AMD (dAMD) appears, that is, progressive macular degeneration of retinal pigment epithelium (RPE) and photoreceptors.
Figure 8. Ophthalmoscopy images of mice treated with NaIO3 on days 3, 7, and 14 showed an increase in the area of retinal pigment loss compared to D0, and OCT images showed that their total retinal thickness was significantly lower than that before treatment at D0.
Figure 9. NalO3 disrupts the integrity of the RPE cell layer. The H&E staining of cross-sections of mouse retinas showed RPE layer rupture on the third day after tail vein injection of NaIO3, patchy RPE loss, RPE cell aggregation (HE-stained yellow arrows), and photoreceptor cell degeneration; the number of photoreceptor nuclei in the central retina of NaIO3-treated mice was significantly reduced on the third day, and outer nuclear layer (ONL) thickness was thinned.
Figure 10. TUNEL staining shows the death of photoreceptor cells, indicating the degeneration of photoreceptor cells.
Figure 11. Retinal function was analyzed by ERG recordings 3 days after NaIO3 injection, and dark-adapted and light-adapted a- and b-wave amplitudes were significantly reduced in NaIO3-treated groups compared to untreated controls.
With 16 years of experience in the field of custom animal models, Cyagen has independently developed a series of genetically modified knockout (KO), knockin (KI), transgenic (TG), editing and humanized mouse models targeting ophthalmic diseases (e.g., retinitis pigmentosa (RP), retinal degeneration, Leber congenital amaurosis 2 (LCA2), macular degeneration, Leber congenital amaurosis 10 (LCA10), and endothelial corneal dystrophy). We can also cooperate to custom-develop genetically engineered mouse models, fully-humanized mouse models, and surgical models to accelerate your preclinical pharmacodynamics evaluations.
In addition to animal models, Cyagen can also provide a series of pre-clinical ophthalmic pharmacodynamics analysis services, including eye injection and administration, material sampling, detection and analysis, efficacy evaluations, and more. You are welcome to contact us at 800-921-8930 or email to animal-service@cyagen.com for free project consultations.
| Selection of self-developed ophthalmic disease models | ||
|---|---|---|
| Disease | Target Gene | Target Type |
| Age-related Macular Degeneration | hVEGFA | KI, TG, Humanization |
| Macular Degeneration | ABCA4(ABCR) | KO, Humanization |
| Retinitis Pigmentosa | Tub | KO |
| Chronic Retinal Degeneration | Prph2 | KO |
| Leber Congenital Amaurosis 2 | Rpe65 | KO, MU |
| Leber Congenital Amaurosis 4 | Aipl1 | KO |
| Leber Congenital Amaurosis 10 | CEP290 | Humanization |
| Leber Congenital Amaurosis 13 | Rdh12 | KO |
| Retinitis Pigmentosa | RHO | KO, CKO |
| Humanization, Humanization(MU) | ||
| Retinitis Pigmentosa | Mertk | KO, CKO |
| Retinitis Pigmentosa | Rpgr | KO |
| Retinitis Pigmentosa | Crb1 | KO |
| Retinitis Pigmentosa | Rd1(Pde6b) | KO, MU |
| Retinitis Pigmentosa | Rd10(Pde6b) | MU |
| Retinitis Pigmentosa | RP2 | KO, CKO |
| Achromatopsia | Cnga3 | CKO |
| Corneal Endothelial Dystrophy | TCF4 | CKO, Humanization |
| Aniridia | Pax6 | CKO |
| Choroideremia | Chm | CKO |
| Usher Syndrome | USH2A | Humanization, Humanization(MU) |
| Usher Syndrome | Myo7a | CKO |
| Vitelliform Macular Dystrophy | Best1 | KO |
| Juvenile Retinoschisis | Rs1 | KO, CKO |
| Oculocutaneous Albinism Type 1 | Tyr | CKO |
| Oculocutaneous Albinism Type 3 | Tyrp1 | KO, CKO |
| Wolfram Syndrome | Wfs1 | KO, CKO |
| Pseudoxanthoma Elasticum | Abcc6 | KO, CKO |
In addition to animal models, Cyagen has developed an ophthalmic gene therapy platform to solve the long-term difficulties faced by ophthalmic gene therapy. Our platform is equipped with high-end refined small animal ophthalmic equipment and senior professional staff to provide comprehensive pre-clinical ophthalmic pharmacodynamics analysis services, including eye injection and administration, material sampling, detection and analysis, efficacy evaluations, and more. You are welcome to contact us at 800-921-8930 or email to animal-service@cyagen.com for free project consultations.
It is sincerely hoped that with the efforts of all parties, more gene therapy methods will enter clinical trials and help the congenitally blind to see the dawn as soon as possible.
